Results 191 to 200 of about 31,452 (261)

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

Advanced Science, Volume 13, Issue 44, 7 August 2026.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng, Chao He, Zhibin He, Hongbo Chen, Fang Cheng, Yongjiang Zheng   +5 more
wiley   +1 more source

Engineering the Future of ADCs in Non-Small Cell Lung Cancer. [PDF]

Oncol Res
Kim MR, Lau J, Maffezzoli M, Banna GL.
europepmc   +1 more source

Epitope‐Resolved Digital SERS Profiling of Structurally Dynamic Antigens via a Multi‐Epitope Bispecific Antibody Framework

Advanced Science, Volume 13, Issue 46, 17 August 2026.
A multi‐epitope digital surface‐enhanced Raman spectroscopy framework enables epitope‐resolved immunoprofiling by integrating bispecific antibody fragments with spectrally encoded nanotags. This approach decouples binding events into independent digital channels, allowing structure‐aware antigen analysis.
Jing Wang, Quan Zhou, Kym Lowry, Christopher B. Howard, Matt Trau   +4 more
wiley   +1 more source

Non-factor Therapies in Hemophilia: Mechanisms, Clinical Evidence, Patient Management, and Future Perspectives. [PDF]

Adv Ther
Nakajima Y, Nogami K.
europepmc   +1 more source

Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis

American Journal of Hematology, Volume 101, Issue 8, Page 1903-1914, August 2026.
ABSTRACT High dose melphalan (HDM) with autologous stem cell transplant is an established treatment for systemic light chain amyloidosis, but its incremental benefit in the era of effective standard intensity therapy is unknown. We retrospectively analyzed 475 transplant‐eligible patients who completed standard intensity treatment with or without HDM ...
Maximilian J. Steinhardt, Ute Hegenbart, Tamer Hellou, Sara Oubari, Murielle Roussel, Rahel Schwotzer, Francis Buadi, David Dingli, Moritz Binder, Taxiarchis Kourelis, Saurabh S. Zanwar, Max J. Rieger, Caroline Morbach, Vladimir Cejka, Bernhard Gerber, Stefan Störk, Hermann Einsele, Shaji Kumar, Morie Gertz, Alexander Carpinteiro, K. Martin Kortum, Eli Muchtar, Angela Dispenzieri, Stefan Schönland   +23 more
wiley   +1 more source

T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges. [PDF]

Cell Rep Med
Paczesny S, Barwe SP, Gopalakrishnapillai A, Cheung NV.   +3 more
europepmc   +1 more source

Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis

American Journal of Hematology, Volume 101, Issue 8, Page 1928-1937, August 2026.
ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and ...
Murali Janakiram, Carlyn R. Tan, Hira Mian, Chiung‐Yu Huang, Rakesh Popat, Joaquín Martínez‐Lopez, Efsthathios Kastritis, Wee‐Joo Chng, Prashant Kapoor, Mrugakshi Dave, Susan Bal, Laurent Garderet, Andre De Menezes Silva Corraes, Christine Riedhammer, Torsten Steinbrunn, Magdalene Corona, Chandramouli Nagarajan, Hermann Einsele, Tom Martin, Amrita Krishnan, Yi Lin, Nadine Abdullah, Niels Abildgaard, Ingerid Abrahamsen, Melissa Alsina, Kenneth Anderson, Hervé Avet‐Loiseau, Ashraf Badros, Nizar Jacques Bahlis, Susan Bal, Rahul Banerjee, Dina Ben‐Yehuda, Jesús G. Berdeja, Michele Cavo, Ajai Chari, Wen‐Ming Chen, Marta Chesi, Wee‐Joo Chng, Yael Cohen, Adam Cohen, Gordon Cook, Luciano Costa, Andrew Cowan, Carlos Fernández de Larrea, Benjamin Derman, Juan Du, Hermann Einsele, Gösta Gahrton, Francesca Gay, Sergio A. Giralt, Simon Harrison, J Jean‐Luc Harousseau, Joy Ho, Doris Hansen, Maung Myo Htut, Andrzej J. Jakubowiak, Murali Janakiram, Prashant Kapoor, Efstathios Kastritis, Jonathan Kaufman, Kihyun Kim, Amrita Krishnan, Shaji Kumar, Chara Kyriakou, Xavier Leleu, Yi Lin, Sagar Lonial, Matthew frigault, Johan L. Lund, Elias Mai, Angelo Maiolino, Elias Mai, Angelo Maiolino, Sireesha Asoori Maringanti, Thomas Martin, Joaquin Martinez‐Lopez, María‐Victoria Mateos, Giampaolo Merlini, Hira Mian, Joseph Mikhael, Monique Minnema, Philippe Moreau, Gareth Morgan, Nikhil Munshi, Omar Nadeem, Chandramouli Nagarajan, Ajay Nooka, Michael O'Dwyer, Rimke Oostvogel, Alberto Orfao, Paula Rodriguez Otero, Darren Pan, Krina Patel, Rashesh Popat, Noemí Puig   +94 more
wiley   +1 more source

Bispecific antibodies targeting herpes simplex virus glycoproteins B and D. [PDF]

Front Immunol
Atanasiu D, Saw WT, Cairns TM, Friedman HM, Cohen GH.   +4 more
europepmc   +1 more source

Advances in translational lung cancer research in 2025: a narrative review. [PDF]

Transl Lung Cancer Res
Xu Y, Kuang Y, Guo Y, Lou Y.
europepmc   +1 more source

Antibody targeting of the TNF-TNFR2 axis to overcome tumor immune resistance. [PDF]

Front Immunol
Kang X, Tong X, Wang S.
europepmc   +1 more source